by David Wright
A small prospective observational study suggests a highly targeted, incisionless procedure may help some people with severe treatment-resistant depression. The findings are intriguing—but they are early evidence from a specialized program, not a new routine treatment.
Key Takeaway
The right response to a promising early study is neither dismissal nor hype. For severe treatment-resistant depression, established evaluation and treatment pathways still come first while specialized procedures are studied more rigorously.
What researchers reported at ASTRO 2026
On September 28, the American Society for Radiation Oncology reported results from a prospective observational study of 20 people with severe treatment-resistant depression who underwent stereotactic radiosurgical capsulotomy. The procedure uses highly focused radiation to create a very small lesion in a brain pathway involved in mood-related circuitry, without an incision or an implanted device.
These were not people with a first episode of depression or a modest treatment history. All had received cognitive therapy and multiple medications, and many had also not improved with treatments such as ketamine, transcranial magnetic stimulation or electroconvulsive therapy. That matters because the results apply to a highly selected group with unusually difficult-to-treat illness.
The signal was meaningful—but the study was small
Among the 18 participants evaluated with depression symptom scores, the average Beck Depression Inventory score fell 53% at the point of greatest improvement. Eleven of 18 had scores fall by at least half, and 16 showed some numerical improvement. At the last follow-up, the average score remained 47% below the pretreatment average. Median follow-up was a little over three years.
The report also described a large reduction in suicidal ideation: 14 of 20 participants reported suicidal thoughts before treatment and one did afterward. That is an important signal in a population with severe illness, but an uncontrolled 20-person study cannot prove the procedure caused the change or predict how often the result would occur in a broader population.
Safety findings need the same careful interpretation
Researchers reported no overall evidence of cognitive decline, neurologic deficits, apathy or personality change during follow-up. Three participants experienced moderate treatment-related effects involving headache or dizziness; two also had larger-than-intended tissue changes visible on imaging, and all recovered with steroid treatment.
Those findings are reassuring within this small cohort, but they do not make the procedure low-risk or routine. Modern stereotactic techniques are much more precise than historical psychosurgery, yet this is still an ablative intervention involving the brain. Long-term safety, patient selection and informed consent remain central questions.
Where this fits beside established brain-stimulation treatments
Treatment-resistant depression does not have one universal next step. Depending on diagnosis, severity, medical history and prior treatment, specialty care can include medication strategies, evidence-based psychotherapy, transcranial magnetic stimulation, electroconvulsive therapy and other approaches. NIMH describes ECT as an established treatment for severe depression and notes that repetitive TMS is FDA-cleared for treatment-resistant depression.
Radiosurgical capsulotomy is different: it creates a permanent lesion rather than delivering a reversible course of stimulation. The ASTRO investigators themselves emphasized that the procedure should remain limited to experienced multidisciplinary teams while larger controlled studies clarify benefit and risk.
What patients and families can do now
If depression remains severe after multiple adequate treatment trials, the practical next step is a careful review of what has actually been tried: diagnoses and co-occurring conditions, medication dose and duration, psychotherapy type and engagement, sleep and substance factors, medical contributors, and whether evidence-based specialty treatments have been discussed.
A second opinion at a specialty mood-disorders or brain-stimulation program can be reasonable when symptoms remain disabling. The goal is not to chase every new intervention. It is to make sure established options have been evaluated systematically and that emerging options are considered only in settings capable of appropriate screening, consent, monitoring and follow-up.
Keep hope and evidence in the same room
For someone who has lived with years of severe depression, new data can carry enormous emotional weight. It is appropriate to feel hopeful. It is equally important to protect that hope from becoming certainty before the evidence is mature.
The responsible interpretation is that this study provides a reason for further research. It does not establish a standard of care, and it does not mean that every person with treatment-resistant depression is a candidate. Good mental-health care remains individualized, stepped, collaborative and safety-focused.
Questions Readers Often Ask
Does this mean radiosurgery is now an approved routine treatment for depression?
No. The study is early, small and observational. The investigators and ASTRO explicitly called for larger studies before the approach can be understood as part of routine care.
Is this the same as TMS or ECT?
No. TMS and ECT use forms of brain stimulation. Radiosurgical capsulotomy creates a targeted, permanent lesion in a brain pathway and is a fundamentally different intervention.
What should someone do if standard depression treatment has not worked?
Seek a structured specialty review of diagnosis, prior treatment adequacy, co-occurring conditions, safety and established treatment-resistant-depression options. Emerging procedures should be discussed only with experienced specialty teams.
Bottom Line
The 2026 radiosurgery findings deserve attention because the participants had unusually severe, persistent illness and some experienced durable improvement. They also deserve restraint. A 20-person uncontrolled study is a signal—not a verdict. The most useful next step is a rigorous treatment review and, when appropriate, referral to a specialty program that can place both established and emerging options in context.
Next Step
If persistent depression is affecting safety, functioning, relationships or quality of life, AHMHW can help organize the whole-person picture and coordinate appropriate next steps alongside specialty psychiatric, neurologic or emergency care when needed.
Sources & Further Reading
- American Society for Radiation Oncology, Sept. 28, 2026 — Incisionless radiosurgery shows promise for severe, treatment-resistant depression
- National Institute of Mental Health — Brain Stimulation Therapies
Educational information only. This article is not a diagnosis, treatment recommendation or substitute for individualized psychiatric or emergency care. If there is an immediate safety concern, use emergency services or 988 in the United States.
0 Comments